309 related articles for article (PubMed ID: 37121469)
1. Effect of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials.
Huang L; Zhang F; Xu P; Zhou Y; Liu Y; Zhang H; Tan X; Ge X; Xu Y; Guo M; Long Y
Adv Nutr; 2023 Jul; 14(4):629-636. PubMed ID: 37121469
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS; Brown TJ; Brainard JS; Biswas P; Thorpe GC; Moore HJ; Deane KH; AlAbdulghafoor FK; Summerbell CD; Worthington HV; Song F; Hooper L
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD003177. PubMed ID: 30019766
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS; Brown TJ; Brainard JS; Biswas P; Thorpe GC; Moore HJ; Deane KH; AlAbdulghafoor FK; Summerbell CD; Worthington HV; Song F; Hooper L
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD003177. PubMed ID: 30521670
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS; Brown TJ; Brainard JS; Biswas P; Thorpe GC; Moore HJ; Deane KH; Summerbell CD; Worthington HV; Song F; Hooper L
Cochrane Database Syst Rev; 2020 Feb; 3(3):CD003177. PubMed ID: 32114706
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Kwak SM; Myung SK; Lee YJ; Seo HG;
Arch Intern Med; 2012 May; 172(9):686-94. PubMed ID: 22493407
[TBL] [Abstract][Full Text] [Related]
6. Fish and Omega-3 Fatty Acids: Sex and Racial Differences in Cardiovascular Outcomes and Cognitive Function.
Welty FK; Daher R; Garelnabi M
Arterioscler Thromb Vasc Biol; 2024 Jan; 44(1):89-107. PubMed ID: 37916414
[TBL] [Abstract][Full Text] [Related]
7. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.
Sarmento Vasconcelos V; Macedo CR; de Souza Pedrosa A; Pereira Gomes Morais E; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011014. PubMed ID: 27536971
[TBL] [Abstract][Full Text] [Related]
8. Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Yokoyama Y; Kuno T; Morita SX; Slipczuk L; Takagi H; Briasoulis A; Latib A; Bangalore S; Heffron SP
J Cardiol; 2022 Nov; 80(5):416-422. PubMed ID: 35914996
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
Harris WS; Dayspring TD; Moran TJ
Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
[TBL] [Abstract][Full Text] [Related]
10. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials.
Martins JG
J Am Coll Nutr; 2009 Oct; 28(5):525-42. PubMed ID: 20439549
[TBL] [Abstract][Full Text] [Related]
11. Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health.
Djuricic I; Calder PC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():383-406. PubMed ID: 36662586
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials.
Yang B; Tseng PT; Hu X; Zeng BY; Chang JP; Liu Y; Chu WJ; Zhang SS; Zhou ZL; Chu CS; Chang CH; Tu YK; Wu YC; Stubbs B; Carvalho AF; Lin PY; Matsuoka YJ; Suen MW; Su KP
Prog Lipid Res; 2022 Nov; 88():101196. PubMed ID: 36341839
[TBL] [Abstract][Full Text] [Related]
13. Statin Use Mitigate the Benefit of Omega-3 Fatty Acids Supplementation-A Meta-Regression of Randomized Trials.
Sethi A; Bajaj A; Khosla S; Arora RR
Am J Ther; 2016; 23(3):e737-48. PubMed ID: 25036814
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality.
Jiang H; Wang L; Wang D; Yan N; Li C; Wu M; Wang F; Mi B; Chen F; Jia W; Liu X; Lv J; Liu Y; Lin J; Ma L
Clin Nutr; 2022 Aug; 41(8):1798-1807. PubMed ID: 35830775
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Fialkow J
Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
[TBL] [Abstract][Full Text] [Related]
16. Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.
Wang IE; Yi S; Block RC; Mousa SA
Nutr Res Rev; 2022 Dec; 35(2):295-307. PubMed ID: 34253265
[TBL] [Abstract][Full Text] [Related]
17. Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease: From fish to pharmaceuticals.
Bosomworth NJ
Can Fam Physician; 2023 Jul; 69(7):459-468. PubMed ID: 37452000
[TBL] [Abstract][Full Text] [Related]
18. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids and cardiovascular prevention: is the jury still out?
Hamilton-Craig C; Kostner K; Colquhoun D; Nicholls SJ
Intern Med J; 2023 Dec; 53(12):2330-2335. PubMed ID: 38105550
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials.
Casula M; Olmastroni E; Gazzotti M; Galimberti F; Zambon A; Catapano AL
Pharmacol Res; 2020 Oct; 160():105060. PubMed ID: 32634581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
